Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyTue, 16 Jul 2024 15:07:57 +0200Thu, 06 Jun 2024 15:45:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0171/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001075-pip04-15-m06Opinion/decision on a Paediatric investigation plan (PIP): Evenity, Romosozumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrinology-Gynaecology-Fertility-Metabolism, PIP number: P/0171/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001075-pip04-15-m06Thu, 06 Jun 2024 15:45:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Evenity, romosozumab, Date of authorisation: 09/12/2019, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/evenityHuman medicines European public assessment report (EPAR): Evenity, romosozumab, Date of authorisation: 09/12/2019, Revision: 5, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/evenityTue, 21 May 2024 09:40:00 +0200Human medicineEvenity : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4465-aa_en.pdfEvenity : EPAR - All Authorised presentationshttps://www.ema.europa.eu/system/files/documents/all-authorised-presentations/h-4465-aa_en.pdfMon, 24 Feb 2020 16:56:00 +0100Human medicine